정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1731 | Active, not recruiting | DEFINE - Evaluating Therapies for COVID-19 | COVID-19 | Drug: Nafamostat Mesilate Drug: TD139 Other: Standard care |
Phase 2 | University of Edinburgh, University of Oxford, Latus Therapeutics | OTHER | 200 | All | 16 Years | NHS Lothian, Edinburgh, United Kingdom |
| 1730 | Recruiting | Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines | COVID-19 | Biological: Ad26.COV2.S Biological: BNT162b2 Biological: mRNA-1273 Biological: mRNA-1273.211 |
Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | NIH | 950 | All | 18 Years ~ 99 Years | Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States University of Maryland Baltimore - Institute of Human Virology, Baltimore, Maryland, United States New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States New York University School of Medicine - Langone Medical Center - Vaccine Center, New York, New York, United States University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh, Pennsylvania, United States University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States The University of Washington - Virology Research Clinic, Seattle, Washington, United States |
| 1729 | Recruiting | Dendritic Cell Vaccine to Prevent COVID-19 | COVID-19 | Biological: AV-COVID-19 | Phase 1 | Indonesia-MoH, Aivita Biomedical, Inc., PT AIVITA Biomedika Indonesia, National Institute of Health Research and Development, Ministry of Health Republic of Indonesia, RSUP Dr. Kariadi Semarang, indonesia, Faculty of Medicine University of Diponegoro, Indonesia | OTHER_GOV | 27 | All | 18 Years | Rumah Sakit Umum Pusat Dr. Kariadi, Semarang, Jawa Tengah, Indonesia |
| 1728 | Completed | Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection | COVID-19 | Biological: AV-COVID-19 Other: GM-CSF |
Phase 1 | Aivita Biomedical, Inc., PT AIVITA Biomedika Indonesia, Indonesia Ministry of Health, National Institute of Health Research and Development, Ministry of Health Republic of Indonesia | INDUSTRY | 27 | All | 18 Years | Rumah Sakit Umum Pusat Dr. Kariadi, Semarang, Jawa Tengah, Indonesia |
| 1727 | Completed | Desidustat in the Management of COVID-19 Patients | COVID-19 | Drug: Desidustat Other: Standard of Care |
Phase 2 | Cadila Healthcare Limited | INDUSTRY | 24 | All | 18 Years | Avant Sante Site 1, Monterrey, Mexico |
| 1726 | Recruiting | Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT | Covid19 Pneumonia | Drug: [18F]FP-R01-MG-F2 | Early Phase 1 | Stanford University, Pliant Therapeutics, Inc. | OTHER | 30 | All | 18 Years | Stanford University, Stanford, California, United States |
| 1725 | Active, not recruiting | Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19 | Hydroxychloroquine Adverse Reaction | Drug: inhalable hydroxychloroquine (HCQ) Drug: supportive and symptomatic treatment |
Not Applicable | Mansoura University | OTHER | 40 | All | 18 Years | Mansoura University Hospital, Mansoura, Outside U.S./Canada, Egypt |
